EMFRET ANALYTICS

Emfret Analytics GmbH & Co. KG is a privately held profitable German biotech company founded in 2002 in Würzburg. The company began operations at the Technologie- und Gründerzentrum Würzburg (TGZ) and relocated to Eibelstadt near Würzburg in 2006.

Emfret has established a globally unique portfolio of anti-platelet receptor antibodies that, for the first time, enabled precise molecular analysis and targeted experimental modulation of platelet function in murine models. These tools have fundamentally advanced mechanistic understanding in thrombosis, hemostasis, and thrombo-inflammation. Today, Emfret antibodies are used in more than 600 research laboratories across academia and the pharmaceutical industry worldwide and are widely regarded as benchmark reagents in platelet research.

In parallel, Emfret has built antibody-based preclinical development programs addressing thrombotic, hemorrhagic, and thrombo-inflammatory diseases.

From its inception, Emfret has maintained a close scientific partnership with the University of Würzburg, one of the world’s leading centers for basic and translational platelet research
(www.platelets.eu).